Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

Business Leaders

HomeAll NewsMost read newsBusiness Leaders Biography 
Portrait de Robert Davis
Age : 70
Public asset : 928,168 USD
Country of residence : Unknown
Linked companies : Intra-Cellular Therapies, Inc.

Summary 
Currently, Robert E. Davis holds the position of Chief Scientific Officer & Senior Vice President at Intra-Cellular Therapies, Inc.

Dr. Davis previously held the position of President & Chief Executive Officer for 3D Pharmaceutical Consultants, Inc., Executive Vice President of ACADIA Pharmaceuticals, Inc. and President, Chief Executive & Scientific Officer at MitoKor, Inc.

Dr. Davis received an undergraduate degree, a doctorate and a graduate degree from the University of Illinois.




Current positions of Robert Davis 
Robert Davis : Personal Network 
Most Read News 
12/01Salesforce shares tumble after surprise exit of co-CEO Taylor
RE
11/23Berkshire Hathaway says Warren Buffett donates shares to family charities
RE
11/30Meta's Zuckerberg says some of Elon Musk's Twitter content approach 'might work'
RE
11/30Juventus has no requirement of additional capital, says Exor's Elkann
RE
11/30Interpol confirms red notice for Angolan billionaire Isabel dos Santos
RE
01:09aThe rise and fall of Wirecard
RE
11/22'Boomerang CEOs' don't always work out; Disney hopes this one bucks trend
RE
11/21Musk says Twitter to hold off relaunching blue check verification
RE
11/29Ryanair's O'Leary says industry most optimistic in 25 years
RE
11/25Elon Musk says Twitter's ban on Trump after Capitol attack was 'grave mistake'
RE
More news


© 2022 People and Ownership :   
Robert Davis : Connections 


Latest news about Robert Davis 
11/21Trending : Merck to Acquire Imago BioSciences for $1.35 Billion
DJ
11/21Merck Eyes Expanded Blood Disorder Drug Pipeline Via $1.35 Billion Buyout of Imago BioSciences
MT
11/17Insider Sell: Doubleverify Holdings
MT
10/27Trending : Merck Raises Outlook After 3Q Beats Expectations
DJ
10/27Transcript : Merck & Co., Inc., Q3 2022 Earnings Call, Oct 27, 2022
CI
10/27Merck lifts full-year forecast as Keytruda sales soar
RE
10/27Merck Names Robert Davis Board Chairman
MT
More news